BACKGROUND AND OBJECTIVES: The soluble receptor of advanced glycation end products (sRAGE) may exert anti-inflammatory protective roles on the vasculature. In contrast, the RAGE ligand S100A12 (also known as EN-RAGE) contributes to inflammation and the development of atherosclerosis in animal models. Whether alterations at this level contribute to the increased mortality observed in patients on dialysis is currently unknown. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Prospective study including 184 prevalent hemodialysis patients and 50 healthy controls matched for age and gender. Plasma concentrations of S100A12 and sRAGE were studied in relation to risk profile and mortality after a median follow-up period of 41 months. RESULTS: S100A12 and sRAGE levels were significantly elevated in hemodialysis patients compared with healthy controls. S100A12 had a strong positive correlation with C-reactive protein and IL-6, whereas sRAGE negatively associated with C-reactive protein. S100A12, but not sRAGE, was independently and positively associated with clinical cardiovascular disease (CVD). During follow-up, 85 (33 cardiovascular-related) deaths occurred. Whereas sRAGE did not predict mortality, S100A12 was associated with both all-cause (per log(10) ng/ml hazard ratio [HR] 1.93, 95% confidence interval [CI] 1.18 to 3.15) and CVD-related (HR 3.23, 95% CI 1.48 to 7.01) mortality, even after adjustment for age, sex, vintage, and comorbidities. Further adjustment for inflammation made the predictive value of S100A12 disappear for all-cause mortality, but still persisted in CVD-related mortality. CONCLUSIONS: Circulating S100A12 and sRAGE are both elevated in hemodialysis patients. However, only S100A12 associates with mortality, partly explained by its links with inflammation.
BACKGROUND AND OBJECTIVES: The soluble receptor of advanced glycation end products (sRAGE) may exert anti-inflammatory protective roles on the vasculature. In contrast, the RAGE ligand S100A12 (also known as EN-RAGE) contributes to inflammation and the development of atherosclerosis in animal models. Whether alterations at this level contribute to the increased mortality observed in patients on dialysis is currently unknown. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Prospective study including 184 prevalent hemodialysis patients and 50 healthy controls matched for age and gender. Plasma concentrations of S100A12 and sRAGE were studied in relation to risk profile and mortality after a median follow-up period of 41 months. RESULTS:S100A12 and sRAGE levels were significantly elevated in hemodialysis patients compared with healthy controls. S100A12 had a strong positive correlation with C-reactive protein and IL-6, whereas sRAGE negatively associated with C-reactive protein. S100A12, but not sRAGE, was independently and positively associated with clinical cardiovascular disease (CVD). During follow-up, 85 (33 cardiovascular-related) deaths occurred. Whereas sRAGE did not predict mortality, S100A12 was associated with both all-cause (per log(10) ng/ml hazard ratio [HR] 1.93, 95% confidence interval [CI] 1.18 to 3.15) and CVD-related (HR 3.23, 95% CI 1.48 to 7.01) mortality, even after adjustment for age, sex, vintage, and comorbidities. Further adjustment for inflammation made the predictive value of S100A12 disappear for all-cause mortality, but still persisted in CVD-related mortality. CONCLUSIONS: Circulating S100A12 and sRAGE are both elevated in hemodialysis patients. However, only S100A12 associates with mortality, partly explained by its links with inflammation.
Authors: Y Yamamoto; I Kato; T Doi; H Yonekura; S Ohashi; M Takeuchi; T Watanabe; S Yamagishi; S Sakurai; S Takasawa; H Okamoto; H Yamamoto Journal: J Clin Invest Date: 2001-07 Impact factor: 14.808
Authors: Loredana G Bucciarelli; Thoralf Wendt; Wu Qu; Yan Lu; Evanthia Lalla; Ling Ling Rong; Mouza T Goova; Bernhard Moser; Thomas Kislinger; Daniel C Lee; Yogita Kashyap; David M Stern; Ann Marie Schmidt Journal: Circulation Date: 2002-11-26 Impact factor: 29.690
Authors: Merlin C Thomas; Con Tsalamandris; Richard MacIsaac; Tanya Medley; Bronwyn Kingwell; Mark E Cooper; George Jerums Journal: Kidney Int Date: 2004-09 Impact factor: 10.612
Authors: A S Detsky; J P Baker; K O'Rourke; N Johnston; J Whitwell; R A Mendelson; K N Jeejeebhoy Journal: JPEN J Parenter Enteral Nutr Date: 1987 Sep-Oct Impact factor: 4.016
Authors: Allen P Burke; Frank D Kolodgie; Arthur Zieske; David R Fowler; Deena K Weber; P Jacob Varghese; Andrew Farb; Renu Virmani Journal: Arterioscler Thromb Vasc Biol Date: 2004-05-13 Impact factor: 8.311
Authors: Marion Hofmann Bowman; Jeannine Wilk; Ahlke Heydemann; Gene Kim; Jalees Rehman; Joseph A Lodato; Jai Raman; Elizabeth M McNally Journal: Circ Res Date: 2009-10-29 Impact factor: 17.367
Authors: Mansi Dalal; Richard D Semba; Kai Sun; Candace Crasto; Ravi Varadhan; Stefania Bandinelli; Jeffrey C Fink; Jack M Guralnik; Luigi Ferrucci Journal: Am J Nephrol Date: 2011-03-09 Impact factor: 3.754
Authors: Naohito Isoyama; Anna Machowska; Abdul Rashid Qureshi; Tae Yamamoto; Björn Anderstam; Olof Heimburger; Peter Barany; Peter Stenvinkel; Bengt Lindholm Journal: Perit Dial Int Date: 2015-10-22 Impact factor: 1.756